Sign up
BIAF

bioAffinity Technologies, Inc. (NASDAQ: BIAF)

Healthcare · Diagnostics & Research

$2.11+0.18 (+9.33%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. BIAF rose 9.33% in the Nov 18 session to $2.11. The borrow fee is 87.55%. Zero active firms cover the stock as of Nov 18, 2026; zero active firms with targets average $6.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 0.7× vs peer median 4.5×

MomentumNeutral

RSI (14) 36.6 (overbought above 70, oversold below 30)

Trend—

—

Short interest10.6% of float

FINRA settlement Oct 30, 2026

BIAF price chart

Price $2.11 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$2.06Nov 18, 2026 session
Previous close
$1.93Nov 17, 2026 close
Day range
$2.06 – $2.20Nov 18, 2026 session
52-week range—
Volume
1.04KNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

BIAF · nasdaq · USD

Last completed session: Nov 17, 2026

Split-adjusted · volume in shares

November 2026 · 12 completed sessions
DateOpenHighLowCloseChangeVolume
1.992.05311.901.93−0.07−3.50%67,866
Open 1.99High 2.0531Low 1.90
2.1252.1321.962.00−0.20−9.090909%74,099
Open 2.125High 2.132Low 1.96
2.34152.35012.172.20−0.14−5.982906%51,554
Open 2.3415High 2.3501Low 2.17
2.432.452.29012.34−0.085−3.505155%48,525
Open 2.43High 2.45Low 2.2901
2.372.602.232.425+0.035+1.464435%76,416
Open 2.37High 2.60Low 2.23
2.472.492.372.39+0.13+5.752212%82,080
Open 2.47High 2.49Low 2.37
2.652.902.252.26−0.455−16.758748%101,644
Open 2.65High 2.90Low 2.25
2.622.82452.622.715+0.115+4.423077%24,832
Open 2.62High 2.8245Low 2.62
2.962.9712.5412.60−0.33−11.262799%76,813
Open 2.96High 2.971Low 2.541
3.113.222.932.93−0.26−8.15047%52,563
Open 3.11High 3.22Low 2.93
2.993.202.9653.19+0.20+6.688963%98,862
Open 2.99High 3.20Low 2.965
2.843.05642.842.99+0.08+2.749141%90,283
Open 2.84High 3.0564Low 2.84

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

12/100Poor

Latest available: Nov 13, 2026 · updates irregularly

Each axis is a 0 to 100 percentile rank among equities

Liquidity18Short91Squeeze32Trend2Momentum4Valuation62Stability3
What each one means
  • Liquidity18

    Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.

  • Short91

    Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.

  • Squeeze32

    Higher scores reflect a higher published Squeeze score within equity peers.

  • Trend2

    Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.

  • Momentum4

    Higher scores reflect stronger 63- and 126-session total returns within equity peers.

  • Valuation62

    Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.

  • Stability3

    Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.

How the Q Score works →

Quantellect signals

Change since Nov 17

Insufficient data · Tide session Nov 17, 2026

Tide30Calm Tide—
Squeeze23Idle—
How the scores work →

How BIAF compares with its industry

Against 44 other US-listed Diagnostics & Research stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Latest-quarter year-over-year sales growth was 19%, higher than 77% of 44 peers.Peer median 8.1% · As of Nov 17, 2026

Points of caution

  1. Trailing-year net margin was -257.3%, with only 0% of 43 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026
  2. Three-month return was -68.5%, with only 10% of 42 peers reporting a lower value.Peer median 4.7% · As of Nov 16, 2026
  3. Current ratio was 1.51, with only 24% of 41 peers reporting a lower value.Peer median 2.63 · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales0.68×4.50×

    Higher than 14% of 44 peers

  • Forward P/E—26.67×

    Not ranked: only 31 of 44 peers report it

  • Price/book1.09×3.74×

    Higher than 14% of 43 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin34.6%55.0%

    Higher than 22% of 41 peers

  • Operating margin−220.8%0.8%
    Bottom 10% of peers

    Higher than 5% of 40 peers

  • Net margin−257.3%0.0%
    Lowest of 43 peers

    Higher than 0% of 43 peers

  • Return on equity—0.0%

    Not ranked: only 41 of 44 peers report it

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year19.0%8.1%

    Higher than 77% of 44 peers

  • 5-year sales growth rate—7.8%

    Not ranked: only 32 of 44 peers report it

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio1.512.63

    Higher than 24% of 41 peers

  • Debt/equity (total borrowings)0.040.45

    Not ranked: only 26 of 44 peers report it

Momentum

Returns are lower than most peers.

  • 1-year return+4.9%+10.8%

    Higher than 43% of 42 peers

  • 6-month return+13.5%+41.9%

    Higher than 33% of 42 peers

  • 3-month return−68.5%+4.7%
    Bottom 10% of peers

    Higher than 10% of 42 peers

Compared with 44 other US-listed Diagnostics & Research stocks · fundamentals as of Nov 15, 2026 · prices as of Nov 16, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

No Coverage

0Strong Buy
0Buy
0Neutral
0Sell
0Strong Sell

Based on 0 active firms as of Nov 18, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$6.00
Average$6.00
High$6.00

As of Nov 18, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026—−$5.89—
Q2 2026—−$0.64—
Q1 2026—−$0.81—
Annual 2025—−$8.66—
Q3 2025—−$4.74—
Q2 2025—−$0.17—
Q1 2025—−$0.16—
Annual 2024−$0.14−$0.75—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All BIAF news →

Company profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics

CEO
Ms. Maria Zannes J.D.
Headquarters
San Antonio, TX, United States
Employees
57
IPO date
Sep 1, 2022
Sector
Healthcare
Industry
Diagnostics & Research

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.